Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

Joyau C, Veyrac G, Dixneuf V, Jolliet P.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):700-6. Epub 2012 Oct 17. Review.

PMID:
22935567
2.

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.

Ko JM, Gottlieb AB, Kerbleski JF.

J Dermatolog Treat. 2009;20(2):100-8. doi: 10.1080/09546630802441234. Review.

PMID:
18923992
3.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
4.

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M.

Br J Dermatol. 2007 Mar;156(3):486-91.

PMID:
17300238
5.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
6.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.

Collamer AN, Guerrero KT, Henning JS, Battafarano DF.

Arthritis Rheum. 2008 Jul 15;59(7):996-1001. doi: 10.1002/art.23835. Review.

7.

Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.

Iborra M, Beltrán B, Bastida G, Aguas M, Nos P.

J Crohns Colitis. 2011 Apr;5(2):157-61. doi: 10.1016/j.crohns.2010.11.001. Epub 2010 Dec 7.

PMID:
21453886
8.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

9.

Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.

Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR.

J Am Acad Dermatol. 2012 Nov;67(5):e179-85. doi: 10.1016/j.jaad.2011.05.038. Epub 2011 Jul 14.

PMID:
21752492
10.

Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.

Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A.

J Am Acad Dermatol. 2017 Feb;76(2):334-341. doi: 10.1016/j.jaad.2016.08.012. Epub 2016 Oct 5. Review.

PMID:
27720274
11.

Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis.

Sauder MB, Glassman SJ.

Int J Dermatol. 2013 May;52(5):624-8. doi: 10.1111/j.1365-4632.2012.05707.x. Epub 2013 Mar 14.

PMID:
23489057
12.

Clinical management of paradoxical psoriasiform reactions during TNF- α therapy.

Navarro R, Daudén E.

Actas Dermosifiliogr. 2014 Oct;105(8):752-61. doi: 10.1016/j.ad.2013.05.007. Epub 2013 Aug 9. Review. English, Spanish.

PMID:
23938073
13.

Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Théophile H, Schaeverbeke T, Miremont-Salamé G, Abouelfath A, Kahn V, Haramburu F, Bégaud B.

Drug Saf. 2011 Jul 1;34(7):577-85. doi: 10.2165/11590200-000000000-00000.

PMID:
21663333
14.

Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.

Włodarczyk M, Sobolewska A, Wójcik B, Loga K, Fichna J, Wiśniewska-Jarosińska M.

World J Gastroenterol. 2014 Jun 14;20(22):7019-26. doi: 10.3748/wjg.v20.i22.7019.

15.

Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.

Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P.

J Rheumatol. 2007 Feb;34(2):380-5. Epub 2006 Oct 1.

PMID:
17013997
16.

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

Puig L, Morales-Múnera CE, López-Ferrer A, Geli C.

Dermatology. 2012;225(1):14-7. doi: 10.1159/000339864. Epub 2012 Aug 10. Review.

PMID:
22890275
17.

Psoriasis Induced by Anti-Tumor Necrosis Factor Alpha Agents: A Comprehensive Review of the Literature.

Ciccarelli F, De Martinis M, Sirufo MM, Ginaldi L.

Acta Dermatovenerol Croat. 2016 Aug;24(3):169-74. Review.

PMID:
27663916
18.

TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2. Review.

PMID:
25887212
19.

[Adverse events during biological therapy -- focusing on dermatological side-effects].

Nagy G, Lukács K, Sziray A, Fazekas K, Florián A, Tamási L, Károlyi Z.

Orv Hetil. 2011 Feb 6;152(6):212-20. doi: 10.1556/OH.2011.28987. Hungarian.

PMID:
21278026
20.

Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.

Wendling D, Balblanc JC, Briançon D, Brousse A, Lohse A, Deprez P, Humbert P, Aubin F.

Joint Bone Spine. 2008 May;75(3):315-8. doi: 10.1016/j.jbspin.2007.06.011. Epub 2008 Feb 11.

PMID:
18329935

Supplemental Content

Support Center